These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19698582)

  • 21. Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development.
    Montgomery S
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 2():5-11. PubMed ID: 24921676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinically relevant drug interactions with new generation antidepressants and antipsychotics].
    Eckert A
    Ther Umsch; 2009 Jun; 66(6):485-92. PubMed ID: 19496045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [How to treat and manage unsatisfactory response?].
    El-Hage W; Fakra E
    Encephale; 2016 Feb; 42(1 Suppl 1):1S39-47. PubMed ID: 26879256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.
    Benkert O; Gründer G; Wetzel H; Hackett D
    J Psychiatr Res; 1996; 30(6):441-51. PubMed ID: 9023787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid onset of action of venlafaxine.
    Montgomery SA
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 2():21-7. PubMed ID: 7622814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
    Fawcett J; Barkin RL
    J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tianeptine: a review of its use in depressive disorders.
    Wagstaff AJ; Ormrod D; Spencer CM
    CNS Drugs; 2001; 15(3):231-59. PubMed ID: 11463130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A risk-benefit assessment of mirtazapine in the treatment of depression.
    Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
    Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic profile and efficacy of venlafaxine.
    Mendlewicz J
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 2():5-13. PubMed ID: 7622816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of the pharmacological and clinical profile of mirtazapine.
    Anttila SA; Leinonen EV
    CNS Drug Rev; 2001; 7(3):249-64. PubMed ID: 11607047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic action lag time and resistance to treatment].
    Peretti CS
    Encephale; 1999 Jun; 25 Spec No 2():49-54. PubMed ID: 10434159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacology of putative early-onset antidepressant strategies.
    Blier P
    Eur Neuropsychopharmacol; 2003 Mar; 13(2):57-66. PubMed ID: 12650947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
    Lenox-Smith A; Conway P; Knight C
    Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.
    Benkert O; Szegedi A; Philipp M; Kohnen R; Heinrich C; Heukels A; van der Vegte-Senden M; Baker RA; Simmons JH; Schutte AJ
    J Clin Psychopharmacol; 2006 Feb; 26(1):75-8. PubMed ID: 16415711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Remission from depression : a review of venlafaxine clinical and economic evidence.
    Han D; Wang EC
    Pharmacoeconomics; 2005; 23(6):567-81. PubMed ID: 15960553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice.
    Singh P; Singh TG
    Indian J Pharmacol; 2015; 47(4):388-93. PubMed ID: 26288470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
    Owen JR; Nemeroff CB
    Depress Anxiety; 1998; 7 Suppl 1():24-32. PubMed ID: 9597349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated hypertension after venlafaxine usage.
    Kıvrak Y; Güvenç TS; Akbulut N; Yağcı I; Cığşar G; Gündüz S; Balcı B
    Case Rep Psychiatry; 2014; 2014():659715. PubMed ID: 25328745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.